Zydus Lifesciences receives USFDA nod for cancer drug

13 Sep 2022 , 12:40 PM

The company said that it has received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug is the therapeutic equivalent generic version of Revlimid (lenalidomide) capsules. The pharmaceutical company said that the drug will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. Speaking on the development Dr. Sharvil Patel, managing director of Zydus Lifesciences said, ?We remain focused on providing patients access to affordable medication and USFDA approval of Lenalidomide Capsules, an important oncology therapy product is yet another step in this endeavour. This underscores our mission to offer quality healthcare solutions that impact lives as we continue to explore opportunities to grow our US business.? According to IQVIA MAT July 2022 data, Lenalidomide had annual sales of $2.86 billion in the United States. The product would be launched in the US market soon, the drug maker said. The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22. Shares of Zydus Lifesciences were up 0.15% to Rs 377.10 on the BSE. Powered by Capital Market – Live News